VerDate Sep<11>2014 17:27 Feb 11, 2021 Jkt 253001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\12FEN1.SGM 12FEN1

• Email: Send comments to Paul.Rodriguez@hhs.gov with the subject line “OMH AI/AN RFI: Center for Indigenous Innovation and Health Equity.”

Submissions received after the deadline will not be reviewed. Respond concisely and in plain language. You may use any structure or layout that presents your information well. You may respond to some or all of our questions, and you can suggest other factors or relevant questions. You may also include links to online material or interactive presentations. Clearly mark any proprietary information and place it in its own section or file. Your response will become government property, and we may publish some of its non-proprietary content.

FOR FURTHER INFORMATION CONTACT: Paul Rodriguez, 1101 Wootton Parkway, Suite 100, Rockville, MD 20852, (240) 453–8208, Paul.Rodriguez@hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background Information

The Office of Minority Health

Authorized under Section 1707 of the Public Health Service Act, 42 U.S.C. 300u–6, as amended, the mission of OMH is to improve the health of racial and ethnic minority populations through the development of health policies and programs that help eliminate health disparities. OMH awards and other activities are intended to support the identification of effective policies, programs and practices for improving health outcomes and to promote sustainability and dissemination of these approaches.

Under the authority of Public Law 116–260 (2021 Consolidated Appropriations Act), Congress called for the creation of a Center for Indigenous Innovation and Health Equity to support efforts including research, education, service, and policy development related to advancing Indigenous solutions to decrease health disparities in AI/AN and NHPI populations. The Center will serve to build capacity and to support efforts including research, education, service, and policy development related to advancing Indigenous solutions. Work in these areas will increase the capacity to identify and address health disparities in AI/AN and NHPI communities. The Center is highly encouraged to engage Indigenous leaders and community partners to address AI/AN and NHPI health disparities focus areas that align with their goals and priorities. The Center is expected to use a dual track approach to address each populations’ needs and tailor indigenous knowledge and practice specific to the AI/AN and NHPI populations. Each track will be parallel and complementary, both rooted in indigenous values and practices appropriate to each population.

The Center’s objectives may include:
• Create an indigenous public health agenda focused on research needs, education, services, and health policies to address AI/AN and NHPI health disparities.
• Serve as a resource to support the development, implementation, evaluation, dissemination, and translation of evidence-based public health interventions in AI/AN and NHPI communities.
• Partner with academic institutions and Indigenous leaders and community partners in health disparities focus areas.
• Train AI/AN and NHPI public health, medical practitioners, students and multi-sector partners.

The Center’s outcomes may include:
• Expand community capacity and knowledge to develop evidence-based program solutions, best practices and policies that address health disparities in AI/AN and NHPI populations.
• Increase utilizations of effective strategies and tools to improve and reduce AI/AN and NHPI health disparities.
• Contribute to improved AI/AN and NHPI health, elimination of health disparities, and achievement of health equity.

II. Request for Information

Through this RFI, OMH is seeking information from the following entities: Federally-recognized Indian Tribes/ American Indian and Alaska Native (AI/AN) Tribes, Tribal organizations, Tribal-serving organizations, Tribal Colleges and Universities, and AI/AN-serving institutions of higher education.

A separate RFI exists to solicit feedback from Native Hawaiian and Pacific Islander (NHPI) communities.

III. Questions

• How might the proposed Center objectives and outcomes listed above meet the needs of AI/AN populations?
• What is the recommended composition and governance infrastructure for the Center?
• Are there specific focus areas and activities this center should address?


Paul Rodriguez,
Senior Advisor for Operations, Office of Minority Health.

[FR Doc. 2021–02953 Filed 2–11–21; 8:45 am]
BILLING CODE 4150–29–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review: Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting:

The meetings will be closed to the public in accordance with the
provisions set forth in sections 522b(c)(4) and 522b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Clinical Neurophysiology, Devices, Neuroprosthetics, and Biosensors.

Date: March 11–12, 2021.
Time: 8:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Abrar Mohamed, Ph.D., Scientific Review Officer, Center for Scientific Review, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827–4043, abrar.mohamed@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Immunology and Microbiology Research.

Date: March 11–12, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mehrdad Mohseni, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5211, MSC 7854, Bethesda, MD 20892, (301) 435–0484, mohsenim@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Computational, Modeling and Biotechnology Management.

Date: March 11, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Susan B. Mallon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1042, mallonb@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Population and Public Health Approaches to HIV/AIDS Study Section.

Date: March 11–12, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Barbara Susanne Mallon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1042, mallonb@mail.nih.gov.

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Population and Public Health Approaches to HIV/AIDS Study Section.

Date: March 11–12, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Philip Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5222, MSC 7852, Bethesda, MD 20892, (301) 435–1137, guerrier@csr.nih.gov.

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Interdisciplinary Clinical Care in Specialty Care Settings Section.

Date: March 11–12, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jose M. Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1137, guerrier@csr.nih.gov.
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Aging Special Emphasis Panel; AD Model.

**Date:** March 9, 2021.

**Time:** 10:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call).

**Contact Person:** Nijaguna Prasad, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute on Aging, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, 301–496–9667, nijaguna.prasad@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: February 8, 2021.

**Miguelina Perez,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–02844 Filed 2–11–21; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; PAR Panel: High Throughput Screening.

**Date:** March 12, 2021.

**Time:** 9:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

**Contact Person:** David Filpula, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6181, MSC 7892, Bethesda, MD 20892, (301) 435–2902, filpuladr@mail.nih.gov.


Dated: February 8, 2021.

**Tyeshia M. Roberson,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–02916 Filed 2–11–21; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of General Medical Sciences Special Emphasis Panel; Review of Innovative Programs to Enhance Research Training (IPERT) Applications.

**Date:** March 19, 2021.

**Time:** 9:30 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (Video Meeting).

**Contact Person:** Rebecca H. Johnson, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, 45 Center Drive, Bethesda, MD 20892, 301–594–2771, johnsonrh@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: February 8, 2021.

**Miguelina Perez,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–02843 Filed 2–11–21; 8:45 am]

BILLING CODE 4140–01–P